Mr. Huang Chaoran joined Chengdu New Radiomedicine Technology Co., Ltd. in 2023 and is theChief Technology Officer. Mr. Huang is a PhD in Chemistry from Institute of Chemistry, Chinese Academy of Sciences, and received his bachelor’s degree and master’s degree in Chemistry from Peking University. He worked at State Key Laboratory of Membrane Biology which was jointly operated by the Chinese Academy of Sciences, Tsinghua University and Peking University. Dr. Huang relocated to the United States and conducted researches in chemistry, biology, pharmaceutical sciences and medicine at University of Tennessee at Knoxville, College of Pharmacy of University of Illinois at Chicago, NIH Biomedical Mass Spectrometry Resource at Washington University. Dr. Huang started to work in the pharmaceutical industry in 1990s, with several major pharmaceutical companies, such as Bristol-Myers Squibb, Takeda and Biogen, in charge of research and production management at different development stages. . Dr. Huang also served as corporate executives at NeuForm Pharmaceuticals and Eubulus Biotechnology.

Dr. Huang has more than 20 years of experience in biopharmaceutical R&D and management, Dr. Huang took leadership role and also participated in the early, middle and late stages of chemical and biogical drug R&D, including clinical studies, regulatory affairs, manufacturing and life cycle management. Dr. Huang brings knowledge and experience in pharmacology, toxicology, clinical pharmacology and translational medicine as well as the drug manufacturing and regulatory affairs.

Dr. Huang brings to the company the knowledge and experience in pharmacology, toxicology, clinical pharmacology and translational medicine as well as manufacture and regulatory.